Hedley, David W.

Biography

Dr Hedley trained in internal medicine and medical oncology in the UK, including a three year thesis project on tumour immunology at the Royal Marsden Hospital/Institute for Cancer Research, University of London. From 1981-89 he was junior faculty at the University of Sydney, Australia, with staff positions as medical oncologist, Royal Prince Alfred Hospital, Sydney, and head of the flow cytometry laboratory, Ludwig Institute for Cancer Research. In 1990 he was appointed as a clinician/scientist in medical oncology at Princess Margaret Hospital, and senior scientist, Ontario Cancer Institute, with the rank of associate professor of medicine, University of Toronto. Since 1998 he has been a full professor, with cross appointments in the Departments of Medical Biophysics and Laboratory Medicine and Pathobiology. His major laboratory focus is on cancers arising in the pancreas and biliary tract, and aligns closely to the clinic in order to understand the high lethality of these cancers, and to explore novel approaches to treatment.   Dr Hedley trained in internal medicine and medical oncology in the UK, including a three year thesis project on tumour immunology at the Royal Marsden Hospital/Institute for Cancer Research, University of London. From 1981-89 he was junior faculty at the University of Sydney, Australia, with staff positions as medical oncologist, Royal Prince Alfred Hospital, Sydney, and head of the flow cytometry laboratory, Ludwig Institute for Cancer Research. In 1990 he was appointed as a clinician/scientist in medical oncology at Princess Margaret Hospital, and senior scientist, Ontario Cancer Institute, with the rank of associate professor of medicine, University of Toronto. Since 1998 he has been a full professor, with cross appointments in the Departments of Medical Biophysics and Laboratory Medicine and Pathobiology. His major laboratory focus is on cancers arising in the pancreas and biliary tract, and aligns closely to the clinic in order to understand the high lethality of these cancers, and to explore novel approaches to treatment.  

Research Interest

Focus on cancer biology and treatment; emphasis on pancreatic cancer which is highly aggressive and difficult to treat. Lab makes extensive use of patient-derived xenografts that recapitulate the pathophysiology and genomic heterogeneity of pancreatic cancer patients. Internationally-recognized expertise in development and application of advanced flow cytometry techniques for studying cancer biology. Investigates novel, mechanism-based approaches to individualized treatment. Extensive network of collaborations involving clinical programs, pathology, and basic research.